343 related articles for article (PubMed ID: 24083419)
21. Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Jung CW; Shih LY; Xiao Z; Jie J; Hou HA; Du X; Wang MC; Park S; Eom KS; Oritani K; Okamoto S; Tauchi T; Kim JS; Zhou D; Saito S; Li J; Handa H; Jianyong L; Ohishi K; Hou M; Depei W; Takenaka K; Liu T; Hu Y; Amagasaki T; Ito K; Gopalakrishna P; Akashi K
Leuk Lymphoma; 2015 Jul; 56(7):2067-74. PubMed ID: 25315076
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Arana Yi C; Tam CS; Verstovsek S
Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
[TBL] [Abstract][Full Text] [Related]
23. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.
Guglielmelli P; Biamonte F; Rotunno G; Artusi V; Artuso L; Bernardis I; Tenedini E; Pieri L; Paoli C; Mannarelli C; Fjerza R; Rumi E; Stalbovskaya V; Squires M; Cazzola M; Manfredini R; Harrison C; Tagliafico E; Vannucchi AM; ;
Blood; 2014 Apr; 123(14):2157-60. PubMed ID: 24458439
[TBL] [Abstract][Full Text] [Related]
24. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
25. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract][Full Text] [Related]
26. Emerging drugs for myelofibrosis.
Atallah E; Verstovsek S
Expert Opin Emerg Drugs; 2012 Dec; 17(4):555-70. PubMed ID: 23186315
[TBL] [Abstract][Full Text] [Related]
27. Ruxolitinib: a new treatment option for myelofibrosis.
Ganetsky A
Pharmacotherapy; 2013 Jan; 33(1):84-92. PubMed ID: 23307549
[TBL] [Abstract][Full Text] [Related]
28. Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
Miller CB; Komrokji RS; Mesa RA; Sun W; Montgomery M; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):479-487. PubMed ID: 28606598
[TBL] [Abstract][Full Text] [Related]
29. Ruxolitinib: the first agent approved for myelofibrosis.
Verstovsek S
Clin Adv Hematol Oncol; 2012 Feb; 10(2):111-3. PubMed ID: 22402352
[No Abstract] [Full Text] [Related]
30. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
Verstovsek S; Mesa RA; Livingston RA; Hu W; Mascarenhas J
J Hematol Oncol; 2023 Jul; 16(1):82. PubMed ID: 37501130
[TBL] [Abstract][Full Text] [Related]
31. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
32. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK; Griesshammer M; Foltz L; Palumbo GA; Martino B; Palandri F; Liberati AM; le Coutre P; García-Hernández C; Zaritskey A; Tavares R; Gupta V; Raanani P; Giraldo P; Hänel M; Damiani D; Sacha T; Bouard C; Paley C; Tiwari R; Mannelli F; Vannucchi AM
Br J Haematol; 2020 Jun; 189(5):888-903. PubMed ID: 32017044
[TBL] [Abstract][Full Text] [Related]
33. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.
Tefferi A; Pardanani A
Mayo Clin Proc; 2011 Dec; 86(12):1188-91. PubMed ID: 22034658
[TBL] [Abstract][Full Text] [Related]
34. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
[TBL] [Abstract][Full Text] [Related]
35. Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
Mesa RA; Verstovsek S; Gupta V; Mascarenhas JO; Atallah E; Burn T; Sun W; Sandor V; Gotlib J
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):214-221.e1. PubMed ID: 25682576
[TBL] [Abstract][Full Text] [Related]
36. Clarifying the use of ruxolitinib in patients with myelofibrosis.
Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
[TBL] [Abstract][Full Text] [Related]
37. Ruxolitinib.
Becker H; Engelhardt M; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
[TBL] [Abstract][Full Text] [Related]
38. Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?
Breccia M; Molica M; Colafigli G; Alimena G
Expert Rev Hematol; 2015 Aug; 8(4):387-9. PubMed ID: 25915176
[TBL] [Abstract][Full Text] [Related]
39. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
[TBL] [Abstract][Full Text] [Related]
40. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]